CA-HYPERICE
Hyperice, a high-performance wellness brand and innovator of percussion, dynamic air compression, thermal, vibration, and contrast therapy technology, filed 16 additional lawsuits in Federal Court on Tuesday, January 16th, 2024 against Sharper Image, HoMedics, Ekrin Athletics, and more than a dozen others, including retailers CVS, Costco, Walgreens and Kohl’s, related to the sale of percussive massage guns, alleging infringement of Hyperice's patented percussion massage technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240118052531/en/
Hypervolt 2 Pro from Hyperice (Photo: Business Wire)
In the lawsuits, which targeted both massage gun direct sellers and numerous retailers, Hyperice asserted its recently-issued U.S. Patent No. 11,857,482, which claims technology dating back to 2013 that is utilized in nearly all massage guns on the market today. Hyperice made national headlines in 2018, launching the Hypervolt, the world’s first “modern-day” massage gun, featuring a brushless motor system, variable speed settings, and QuietGlide® technology. The success and rapid scale of the Hypervolt led to an influx of massage gun brands entering the market to replicate this technology, including the aforementioned parties. Hyperice sells numerous products embodying the patented technology, including its Hypervolt Go 2, Hypervolt 2, and Hypervolt 2 Pro.
In the lawsuits, Hyperice contends that several Sharper Image, HoMedics, Ekrin Athletics, and other products infringe Hyperice’s IP, including but not limited to the Sharper Image Powerboost line, and the Ekrin Athletics massage guns, along with the HoMedics, TRAKK, Eleeels, Vybe, Osaki, LifePro, and other lines of massage guns. In the coming weeks, Hyperice intends to file additional lawsuits against many other sellers and retailers believed to have infringed on this patent. Hyperice has also filed a series of related patent applications to further enhance the scope and scale of protection around the percussion category at large.
This announcement follows legal action taken by Hyperice on January 3rd, where Hyperice sued Therabody, maker of the Theragun and TheraFace products, in Federal Court for patent infringement, contending that numerous Therabody products infringe, including Theragun Elite, Theragun PRO, Theragun Prime, Theragun Mini, Theragun Sense, and TheraFace PRO. Hyperice will add additional products in the lawsuit against Therabody including the Theragun Relief, and any new products that are believed to infringe upon the recently issued patent.
“At Hyperice’s core, we develop innovative products and technologies to enhance recovery, performance, and longevity for consumers worldwide,” said Jim Huether, Hyperice CEO. “For any company working to lead and grow a new and emerging market in the technology sector, the inventive process is extremely important. As such, we hold innovation in high regard and safeguard our products and technology by obtaining patents. There are hundreds of millions of dollars of massage guns sold every year in the U.S. alone, and we believe that a vast majority of these massage guns infringe this patent. We will use aggressive legal actions against all infringers to reinstill credibility of the percussion market.”
In 2023, the massage gun market was valued at USD 542.6 million and is expected to reach well over USD 1 billion over the coming years1 with growth being fuelled by the advancement of technology, consumer’s understanding of the benefits, and prioritization of overall wellness and self-care.
“The actions that we have taken today are one part of a larger legal strategy to protect our intellectual property rights. We intend to take additional actions in the coming days and weeks to ensure that our innovative line of percussion massage guns is protected,” said Jon Howell, General Counsel at Hyperice.
UNMATCHED TECHNOLOGY AND INNOVATION
Hyperice dedicates considerable resources to research, develop, and protect its intellectual property. The brand holds hundreds of patents worldwide and will continue to take an assertive approach to protecting all aspects of its intellectual property. In 2021, Hyperice was recognized by Fast Company as one of the world’s most innovative companies. Hyperice has also attracted some of the world’s most prominent athletes and sports leagues as partners and investors, including Patrick Mahomes, Erling Haaland, Jayson Tatum, Naomi Osaka, Rory McIlroy, the NFL, MLB, NBA, UFC, and PGA TOUR.
Hyperice is represented in the lawsuit by Lawrence LaPorte of Lewis Brisbois Bisgaard & Smith LLP, Ben Herbert of Miller Barondess, LLP, and Brian Arnold, Associate General Counsel and Head of IP at Hyperice. Mr. Arnold was previously a patent litigation partner at several firms including Kirkland & Ellis LLP and, most recently, Lewis Roca Rothgerber Christie LLP.
About Hyperice
Hyperice is a technology-driven company with a giant mission, to help everyone on Earth move and live better. For more than a decade, Hyperice has led a global movement at the confluence of recovery and wellness, specializing in percussion (Hypervolt line), dynamic air compression (Normatec line), vibration (Vyper and Hypersphere lines), thermal technology (Venom line), and contrast therapy (Hyperice X). Now, as a holistic high-performance wellness brand, Hyperice is designed for all - from the most elite athletes, leagues, and teams to consumers everywhere looking to unlock the best version of themselves to help them do what they love, more. Recognized as one of Fast Company’s Most Innovative Companies, Hyperice has applied its technology and know-how to industries including fitness, hospitality, healthcare, massage, physical therapy, sports performance, and workplace wellness on a global scale. For more information, visit hyperice.com.
_______________
1 Future Market Insights: Global Massage Gun Market Outlook (2023 to 2033)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240118052531/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GLORY Acquires Remaining Equity Shares in Acrelec Group26.11.2025 16:11:00 CET | Press release
Acrelec becomes a wholly owned subsidiary of Glory Glory Global Solutions (International) Ltd, a wholly-owned subsidiary of GLORY Ltd. [TYO:6457], has announced the acquisition of the remaining equity shares in Acrelec Group SAS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126039437/en/ Acrelec is a global technology company focused on reinventing the customer experience for restaurant and retail brands. Leveraging decades of software, hardware and service expertise, the company develops and integrates new platforms that increase customer engagement, optimize efficiency and improve operations. With over 120,000 installations across more than 70 countries, Acrelec counts many of the world’s best-known restaurant mega-brands among its customers. We announce that Jalel Souissi has left the Acrelec Group following the completion of the recent share acquisition. Jalel Souissi has played a pivotal role in the development and
Andersen Global styrker sin platform i Tyrkiet med tilføjelsen af medlemsvirksomhed26.11.2025 14:49:00 CET | Pressemeddelelse
Andersen Global udvider sin tilstedeværelse i Tyrkiet, efter at Celen Corporate Property Valuation & Counseling Inc. bliver til Andersen i Tyrkiet, hvilket udvider de kompetencer, der tilbydes under Andersen-brandet i landet. Det Istanbul-baserede firma blev stiftet i 1995 og ledes af Managing Partner Guniz Celen med en bred vifte af ydelser til både nationale og internationale kunder. Med ekspertise inden for finansiering af fast ejendom, værdiansættelse af materielle og immaterielle aktiver samt formueforvaltning leverer den tyrkiske afdeling af Andersen løsninger, der understøtter komplekse finansielle beslutninger for kunder i mere end 18 lande. “Vores mission har altid været at levere løsninger på de mest komplekse udfordringer inden for ejendoms- og investeringssektoren,” sagde Guniz. “At blive en del af Andersen-brandet styrker vores kompetencer som en betroet rådgiver og giver os adgang til globale ressourcer, hvilket gør os i stand til at skabe endnu større langsigtet værdi fo
Cegid Acquires Shine to Accelerate the Path of Becoming Europe's Leading Financial Copilot for SMBs and Accountants26.11.2025 14:00:00 CET | Press release
Transformative combination creates a powerhouse for SMBs and accountants, empowering businesses across Europe by integrating leading suites of e-invoicing, digital accounting, business accounts and payments, and HR solutions into a unified platform. Cegid, a European leader in cloud software for finance, accounting, HR, and retail software, and Shine, a fast-growing European fintech unicorn providing digital business accounts and payments, e-invoicing, accounting, and payroll software to small businesses across Europe, announced today that the companies have entered a definitive agreement to join forces to form a European champion and become a leading provider of software for businesses and their accountants. This transformational combination will create the first fully integrated, cloud-native and AI-driven financial hub for SMBs and accounting professionals in Europe – bringing together market-leading capabilities in e-invoicing, accounting, digital business accounts and payments, ta
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma26.11.2025 12:00:00 CET | Press release
If approved, sonrotoclax will become the first BCL2 inhibitor for R/R MCL in the U.S., addressing a high unmet need in an aggressive cancerSonrotoclax previously received Breakthrough Therapy Designation based on clinically meaningful, rapid responses in R/R MCLBeOne Medicines will present the data supporting the NDA and Priority Review for the first time at ASH 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. “Sonrotoclax is advancing with remarkable speed, from Breakthrough Therapy Designation to Priority Review, all within a short window,” said Lai Wang, Ph.D., Global Head of R&D at BeOne.
Modon Holding Announces a Strategic Investment in Wellington Lifestyle Partners, Expanding Its Global Portfolio in Luxury Lifestyle Destination Development26.11.2025 11:15:00 CET | Press release
Modon joins a consortium of investors to elevate Wellington International equestrian showgrounds and develop an ultra-luxury destination integrating residential, hospitality and sports assets in Wellington, Palm Beach County, FloridaStrengthens Modon’s global presence and enables knowledge exchange across large-scale mixed-use, hospitality and lifestyle developments Abu Dhabi-based Modon Holding P.S.C (“Modon”) today announced a strategic investment in Wellington Lifestyle Partners (“WLP”), joining a consortium of existing investors in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125937208/en/ Aerial shot of Wellington International (Photo: AETOSWire) Modon’s investment will support the long-term development of Wellington International equestrian showgrounds and deliver a landmark ultra-luxury real estate development featuring high-end residences, a boutique hotel, a commercial marketplace and a championshi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
